Developing nanosize carrier systems for Amphotericin‐B: A review on the biomedical application of nanoparticles for the treatment of leishmaniasis and fungal infections
- 15 December 2023
- journal article
- review article
- Published by Wiley in Biotechnology Journal
- Vol. 19 (1) , e2300462
Abstract
New formulations of Amphotericin‐B (Am‐B), the most popular therapeutic drug for many human infections such as parasitic and fungal pathogens, are safe, economical, and effective in the world. Several newly designed carrier systems for Am‐B can also be considered orally with sufficient gastrointestinal permeability and good solubility. However, the clinical application of several new formulations of Am‐B with organ cytotoxicity, low bioavailability, high costs, and technical problems have caused some issues. Therefore, more attention and scientific design are required to progress safe and effective drug delivery systems. Currently, the application of nano‐based technology and nanomaterials in the advancement of drug delivery systems exhibits promising outcomes to cure many human systemic infections. Designing novel drug delivery systems including solid lipid nanostructured materials, lipo‐polymersomes, drug conjugates and microneedles, liposomes, polymer and protein‐based nanostructured materials, dendrimers, emulsions, mixed micelles, polymeric micelles, cyclodextrins, nanocapsules, and nanocochleate for Am‐B has many advantages to reducing several related issues. The unique properties of nanostructured particles such as proper morphology, small size, surface coatings, and, electrical charge, permit scientists to design new nanocomposite materials against microorganisms for application in various human diseases. These features have made these nanoparticles an ideal candidate for drug delivery systems in clinical approaches to cure a number of human disorders and currently, several therapeutic nanostructured material formulations are under different stages of clinical tests. Hence, this scientific paper mainly discussed the advances in new formulations of Am‐B for the treatment of human systemic infections and related clinical tests.Keywords
This publication has 49 references indexed in Scilit:
- Exploring the Role of Nanoparticles in Amphotericin B DeliveryCurrent Pharmaceutical Design, 2017
- Efficacy and safety of amphotericin B lipid‐based formulations—A systematic review and meta‐analysisMycoses, 2016
- Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin BInternational Journal of Pharmaceutics, 2016
- Development of 4-sulfated N -acetyl galactosamine anchored chitosan nanoparticles: A dual strategy for effective management of LeishmaniasisColloids and Surfaces B: Biointerfaces, 2015
- Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non‐toxic chemotherapyBritish Journal of Pharmacology, 2015
- Antigen Presenting Cells Targeting and Stimulation Potential of Lipoteichoic Acid Functionalized Lipo-Polymerosome: A Chemo-Immunotherapeutic Approach against Intracellular Infectious DiseaseBiomacromolecules, 2015
- Development of antileishmanial lipid nanocomplexesBiochimie, 2014
- Self Assembled Ionically Sodium Alginate Cross-Linked Amphotericin B Encapsulated Glycol Chitosan Stearate Nanoparticles: Applicability in Better Chemotherapy and Non-Toxic Delivery in Visceral LeishmaniasisPharmaceutical Research, 2014
- New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania sppInternational Journal of Pharmaceutics, 2014
- Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitroJournal of Nanobiotechnology, 2008